World Medical Association throws ethics into the telemedicine equation:
This article was originally published in Clinica
Executive Summary
The World Medical Association is calling for legislation at national level and international agreements to tighten the conditions affecting the installation and use of telemedicine systems. In ethical guidance on the practice of telemedicine, approved at last week's general assembly (Copenhagen, Denmark, October 3-6), the WMA calls for telemedicine to "ideally be used only in cases where a prior in-person relationship existed between a patient and a physician involved in arranging or providing the telemedicine service". The idea is in line with mainstream views on e-record security, for example, but could pose limitations on the wider network-style accessibility that such systems offer. The guidance covers e-prescribing, physician registration, liability and the legal status of electronic medical records. The WMA has also condemned the commercialisation of activities supporting tissue transplantation-related activities.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.